ANZUP
Cancer Trials Group Limited

UNISoN Trial News

www.anzup.org.au

Welcome to the fourth UNISoN Newsletter

Thank you again to the teams across all 19 participating sites for all your hard work and support in recruiting patients to this study.

Since opening in October 2017 you have recruited 63 patients (74%) into Part 1 of the study, across 18 sites, with 21 (43%) of these patients transitioning onto Part 2 of the study. The speed of recruitment far exceeds our projections and expectations, and it humbles us that we have been able to offer an opportunity to people with an unmet treatment need in the non-clear cell renal cell carcinoma landscape.



Current Recruitment

Ian Davis and the team at Box Hill Hospital continue to serve a large part of Victoria, with 12 patients enrolled to date. Royal Brisbane Hospital also continues to be working hard, enrolling 8 patients. Westmead Hospital, Flinders Medical Centre, Adelaide Cancer Centre, Calvary Mater Newcastle, Monash Health, and Northern Cancer Institute are all seeing numerous patients. The national reach of the study has been illustrated with all sites having screened patients.

ANZUP Cancer Trials Group Limited

Recruitment by site

Site No.	Site	No of Patients Screened	# Patients Registered Part 1	# Patients Registered Part 2
1	ACC	4	4	2
2	BMO	7	3	2
3	BOH	0	0	0
4	BXH	14	12	5
5	CAM	4	3	0
6	CMN	5	4	2
7	COL	5	1	1
8	FMC	5	5	1
9	FSH	4	2	0
10	MON	4	4	0
11	NCI	5	4	2
12	PMQ	2	1	1
13	POW	1	1	0
14	RBWH	13	8	2
15	SCU	1	0	0
16	STG	8	3	1
17	SVH	1	1	0
18	TAM	1	1	0
19	WES	6	6	2
	TOTAL:	**90**	**63**	**21**

Unison is a collaboration between ANZUP and BaCT

BaCT Centre for Biostatistics and Clinical Trials

ANZUP ClinTrial Refer app is available for download from iTunes and Google Play now!

Hot Tips

These best practice tips will help you administer the protocol and avoid data queries and protocol deviations:

PI Oversight of Data – As per Section 14.6 of the protocol, Site Principal Investigators are required to confirm the accuracy of completed eCRFs by routinely logging into Viedoc and signing completed forms on a quarterly basis. Reminders will be circulated to sites in March 2019. Patients completing 12 months of treatment and wishing to continue should have all data up to date and signed off.

As per section 7.7.2.1 of the protocol, palliative (limited-field) radiation therapy is permitted in this study. Please ensure that data relating to any radiotherapy administered is entered into Viedoc, by initiating an Unscheduled Visit and selecting the 'Radiotherapy' eCRF.

Creatinine Clearance – a reminder that this needs to be calculated and entered as required on the Biochemsitry eCRF. Some sites are entering EGFR rather than creatinine clearance. Queries are being raised accordingly in Viedoc.

ANZUP Cancer Trials Group Limited



As patients are now transitioning to Part 2 of the study, please ensure that adequate supplies of both Ipilimumab and Nivolumab are available at sites prior to scheduled dosing. Pharmacists are kindly reminded that it can take up to 14 business days for drug orders to reach sites, therefore, careful monitoring of IMP levels at site is required.

Mid ipi/nivo scan has been left in place because patients are progressing on nivo, and you will want to keep a close eye on patients, however, beware of pseudo-progression which is rare with PD1 alone but much more common with ipilimumab. I.e. treat beyond progression if pseudo-progression is suspected.

What can we do for people failed by Immunotherapy? UNICAB Update

Opening March/April 2019 at selected sites

UNICAB: Non-clear cell post Immunotherapy CABozantinib.

A Phase II trial of single agent Cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802).

UNICAB is a clinical trial of second-line cabozantinib in non-clear cell kidney cancers for patients who have been failed by immunotherapy or for whom immunotherapy is unsuitable. The aim of UNICAB is to determine the objective response rate associated with cabozantinib.

UNISoN is rapidly recruiting, and currently there are no suitable follow-on treatment options for patients who are failed by immunotherapy. Cabozantinib as a second line treatment option may be a useful opportunity for these patients. Patients with a non-clear cell RCC who have taken immunotherapy outside of the UNISON trial are also potentially eligible.

UNICAB is currently pending HREC approval and it is anticipated the first sites will open in March/April 2019. An amendment to add additional sites will occur in March 2019.

Invited sites have been contacted by ANZUP and BaCT. Please contact **Laura Galletta** BaCT Clinical Trial Manger to find out more about this study.



ANZUP Cancer Trials Group Limited

UNISoN Post-Study Access to Nivolumab

With the first patients completing Part 1 of the study from the 20th November, we are now facing the undreamed-of situation where patients who may still be deriving clinical benefit with Nivolumab, decide with you, their treating physician, that they may wish to continue further treatment.

The UNISoN protocol allows for a continuation of Nivolumab beyond 12 months under the following conditions (Section 8.1):

Clinicians may wish to continue study treatment for participants who experience an ongoing complete response, partial response or stable disease and who are still deriving investigator assessed clinical benefit after 12 months of treatment with nivolumab (in either Part 1 or Part 2 of the trial).

After discussion with the Coordinating Principal Investigator, participants treated with 12 *months of nivolumab may be permitted to continue treatment with nivolumab as long as they meet all of the following criteria:*



1. Investigator-assessed clinical benefit
2. No evidence of progressive disease (by RECIST 1.1)
3. Continue to meet all other study protocol eligibility criteria (participants who have experienced a complete response or who otherwise do not have measurable disease are permitted)
4. Tolerance of study drug
5. Stable ECOG performance status (0-1)

Our supporters at BMS have agreed to support continued treatment for these patients, with the following stipulations:

a) Ensuring all data up until the End of Treatment visit has been entered, cleaned and signed off by the site PI.

b) As per Section 8.1 of the protocol, the patient will be considered to have concluded their participation in the treatment phase and will have entered the follow-up phase of the study. This means that we will not be capturing treatment administration or protocol defined data points on these patients in Viedoc, other than what is captured during Follow-Up visits.

c) Ordering and shipping of Nivolumab for these patients to occurs via the same process that is currently in place for ordering drug (i.e. via the BMS/Bracket IWRS system)

d) Prior to continuing treatment, evidence has been provided confirming an absence of progressive disease (by RECIST 1.1) – copies of the latest CT report/RECIST worksheet are mandatoryrequested for review please.

e) Maximum duration of treatment: We request that sites plan to treat patients for an additional 6 months at first, then discuss/re-evaluate each patient with the CPI and study team on a case by case basis.

UNISoN key contacts

- **Clinical trial operations, BaCT E:** laura.galletta@petermac.org **T: +61 3 8559 7529**
- **Sponsor queries (e.g. site payments, contracts) E:** margaret.mcjannett@anzup.org.au
- **Study PI** A/Prof Craig Gedye **E:** craig.gedye@newcastle.edu.au
- **Hunter Cancer Biobank E:** hrca-biobank@newcastle.edu.au **T: +61 2 4042 0313**

Otherwise, please contact your site PI with any initial queries